Report cover image

Global Neutropenia Treatment Market Growth, Size, Trends Analysis - By Treatment Type, Drug Type, By Route of Administration, By Indication, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Publisher SPER Market Research Pvt. Ltd.
Published Jun 19, 2025
Length 284 Pages
SKU # SPER20222473

Description

Neutropenia Treatment Market Introduction and Overview

According to SPER market research, ‘Global Neutropenia Treatment Market Size- By Treatment Type, Drug Type, By Route of Administration, By Indication, By Distribution Channel – Regional Outlook, Competitive Strategies and Segment Forecast to 2034’ state that the Global Neutropenia Treatment Market is predicted to reach 23.12 billion by 2034 with a CAGR of 4.33%.

Neutropenia is a disease marked by a low white blood cell (WBC) count, which helps the body resist infections. It can be caused by various factors, including infections, chemotherapy, inherited bone marrow issues, autoimmune diseases, and certain medications. Neutrophils, the WBCs involved, are produced in the bone marrow found in larger bones.

Restraints:

High treatment costs: This is a significant challenge. Neutropenia treatments, particularly advanced therapy such as Colony-Stimulating Factors (CSFs), can be rather costly. This high cost may limit access for many patients, particularly in areas with limited healthcare coverage or high out-of-pocket costs. It also has a substantial financial impact on individuals and healthcare systems.

Scope of the report:

Report Metric Details
Market size available for years 2021-2034
Base year considered 2024
Forecast period 2025-2034

Segments covered

By Treatment Type, By Drug Type, By Route of Administration, By Indication, By Distribution Channel

Regions covered

North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa

Companies Covered

Amgen Inc, BeyondSpring Inc, Biocon Biologics Inc, Cellerant Therapeutics, Coherus BioSciences, Inc, CuraTeQ Biologics Pvt. Ltd, Evive Biotech, Kyowa Kirin Co., Ltd, Pfizer Inc, Sandoz Inc.

Global Neutropenia Treatment Market Segmentation:

By Treatment Type: Based on the Treatment Type, Global Neutropenia Treatment Market is segmented as; CSF, Antibiotics, Antifungal, Antiviral.

By Drug Type:

Based on the Drug Type, Global Neutropenia Treatment Market is segmented as; Branded, Biosimilar.

By Route of Administration: Based on the Route of Administration, Global Neutropenia Treatment Market is segmented as; Oral, Parenteral.

By Indication: Based on the Indication, Global Neutropenia Treatment Market is segmented as; Chemotherapy-induced neutropenia, Cyclic neutropenia, Idiopathic neutropenia, Congenital neutropenia.

By Distribution Channel:

Based on the Distribution Channel, Global Neutropenia Treatment Market is segmented as; Hospital pharmacies, Retail pharmacies, Online pharmacies.

By Region:

This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Table of Contents

284 Pages
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPERs internal database
2.1.4. Premium insight from KOLs
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTERs Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Neutropenia Treatment Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Neutropenia Treatment Market
7. Global Neutropenia Treatment Market, By Treatment Type (USD Million) 2021-2034
7.1. Colony-stimulating factors (CSFs)
7.2. Antibiotics
7.3. Antifungals
7.4. Antivirals
7.5. Other treatment types
8. Global Neutropenia Treatment Market, By Drug Type (USD Million) 2021-2034
8.1. Branded
8.2. Biosimilars
9. Global Neutropenia Treatment Market, By Route of Administration (USD Million) 2021-2034
9.1. Oral
9.2. Parenteral
10. Global Neutropenia Treatment Market, By Indication (USD Million) 2021-2034
10.1. Chemotherapy-induced neutropenia
10.2. Cyclic neutropenia
10.3. Idiopathic neutropenia
10.4. Congenital neutropenia
11. Global Neutropenia Treatment Market, By Distribution Channel (USD Million) 2021-2034
11.1. Hospital pharmacies
11.2. Retail pharmacies
11.3. Online pharmacies
12. Global Neutropenia Treatment Market, (USD Million) 2021-2034
12.1. Global Neutropenia Treatment Market Size and Market Share
13. Global Neutropenia Treatment Market, By Region, (USD Million) 2021-2034
13.1. Asia-Pacific
13.1.1. Australia
13.1.2. China
13.1.3. India
13.1.4. Japan
13.1.5. South Korea
13.1.6. Rest of Asia-Pacific
13.2. Europe
13.2.1. France
13.2.2. Germany
13.2.3. Italy
13.2.4. Spain
13.2.5. United Kingdom
13.2.6. Rest of Europe
13.3. Middle East and Africa
13.3.1. Kingdom of Saudi Arabia
13.3.2. United Arab Emirates
13.3.3. Qatar
13.3.4. South Africa
13.3.5. Egypt
13.3.6. Morocco
13.3.7. Nigeria
13.3.8. Rest of Middle-East and Africa
13.4. North America
13.4.1. Canada
13.4.2. Mexico
13.4.3. United States
13.5. Latin America
13.5.1. Argentina
13.5.2. Brazil
13.5.3. Rest of Latin America
14. Company Profile
14.1. Amgen Inc
14.1.1. Company details
14.1.2. Financial outlook
14.1.3. Product summary
14.1.4. Recent developments
14.2. BeyondSpring Inc
14.2.1. Company details
14.2.2. Financial outlook
14.2.3. Product summary
14.2.4. Recent developments
14.3. Biocon Biologics Inc
14.3.1. Company details
14.3.2. Financial outlook
14.3.3. Product summary
14.3.4. Recent developments
14.4. Cellerant Therapeutics
14.4.1. Company details
14.4.2. Financial outlook
14.4.3. Product summary
14.4.4. Recent developments
14.5. Coherus BioSciences, Inc
14.5.1. Company details
14.5.2. Financial outlook
14.5.3. Product summary
14.5.4. Recent developments
14.6. CuraTeQ Biologics Pvt. Ltd
14.6.1. Company details
14.6.2. Financial outlook
14.6.3. Product summary
14.6.4. Recent developments
14.7. Evive Biotech
14.7.1. Company details
14.7.2. Financial outlook
14.7.3. Product summary
14.7.4. Recent developments
14.8. Kyowa Kirin Co., Ltd
14.8.1. Company details
14.8.2. Financial outlook
14.8.3. Product summary
14.8.4. Recent developments
14.9. Pfizer Inc
14.9.1. Company details
14.9.2. Financial outlook
14.9.3. Product summary
14.9.4. Recent developments
14.10. Sandoz Inc
14.10.1. Company details
14.10.2. Financial outlook
14.10.3. Product summary
14.10.4. Recent developments
14.11. Others
15. Conclusion
16. List of Abbreviations
17. Reference Links

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us